Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Globe Newswire•11/08/2026•17:21 ET
0
Whiz Insights
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities.
Get started
Create a free account to read the full story.